USD
$0.00
(0.00%
)At Close (As of Nov 28, 2025)
$22.53M
Market Cap
-
P/E Ratio
-0.25
EPS
$4.05
52 Week High
$1.65
52 Week Low
HEALTHCARE
Sector
| Field | Value (SGD) |
|---|---|
| Gross Profit | $52K |
| Total Revenue | $52K |
| Cost Of Revenue | $23K |
| Costof Goods And Services Sold | $23K |
| Operating Income | -$2.6M |
| Selling General And Administrative | $1.2M |
| Research And Development | $1.4M |
| Operating Expenses | $1.9M |
| Investment Income Net | - |
| Net Interest Income | $297K |
| Interest Income | $318K |
| Interest Expense | $15K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $92K |
| Income Before Tax | -$1.9M |
| Income Tax Expense | - |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$2.5M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$1.9M |
| Ebitda | -$1.8M |
| Net Income | -$1.9M |
| Field | Value (SGD) |
|---|---|
| Total Assets | $7.4M |
| Total Current Assets | $4.4M |
| Cash And Cash Equivalents At Carrying Value | $3.6M |
| Cash And Short Term Investments | $3.6M |
| Inventory | $614K |
| Current Net Receivables | $14K |
| Total Non Current Assets | $3M |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | $68K |
| Intangible Assets Excluding Goodwill | $68K |
| Goodwill | $260 |
| Investments | - |
| Long Term Investments | $221K |
| Short Term Investments | $200K |
| Other Current Assets | $126K |
| Other Non Current Assets | - |
| Total Liabilities | $750K |
| Total Current Liabilities | $444K |
| Current Accounts Payable | $28K |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $34K |
| Total Non Current Liabilities | $306K |
| Capital Lease Obligations | $31K |
| Long Term Debt | $394K |
| Current Long Term Debt | $38K |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $339K |
| Other Current Liabilities | $382K |
| Other Non Current Liabilities | - |
| Total Shareholder Equity | $6.6M |
| Treasury Stock | - |
| Retained Earnings | -$11M |
| Common Stock | $17M |
| Common Stock Shares Outstanding | $12M |
| Field | Value (SGD) |
|---|---|
| Operating Cashflow | -$1.7M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $246K |
| Capital Expenditures | $1M |
| Change In Receivables | - |
| Change In Inventory | - |
| Profit Loss | - |
| Cashflow From Investment | $495K |
| Cashflow From Financing | -$33K |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | $0 |
| Dividend Payout Common Stock | $0 |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | - |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$1.8M |
| Field | Value (SGD) |
|---|---|
| Gross Profit | $52K |
| Total Revenue | $52K |
| Cost Of Revenue | $23K |
| Costof Goods And Services Sold | $23K |
| Operating Income | -$2.6M |
| Selling General And Administrative | $1.2M |
| Research And Development | $1.4M |
| Operating Expenses | $1.9M |
| Investment Income Net | - |
| Net Interest Income | $297K |
| Interest Income | $318K |
| Interest Expense | $15K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $92K |
| Income Before Tax | -$1.9M |
| Income Tax Expense | - |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$2.5M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$1.9M |
| Ebitda | -$1.8M |
| Net Income | -$1.9M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
CytoMed Therapeutics Limited (GDTC) is an innovative pre-clinical biopharmaceutical company based in Singapore, dedicated to advancing cell-based immunotherapies for the treatment of diverse cancer types. By leveraging state-of-the-art technology and proprietary research, the firm develops therapeutic candidates that address critical unmet needs in oncology. With a promising pipeline and a strong commitment to scientific excellence, CytoMed positions itself as a compelling opportunity for institutional investors seeking exposure to the rapidly evolving cancer immunotherapy market.